Our Programs

NCCN 2011 Congress Series: Gastrointestinal Cancers™

Login now to start this presentation. If you are not currently a member, please Register here.

Username:
Password:


Presenters



COLORECTAL CANCER

Treatment of Localized Rectal Cancer
Christopher G. Willett, MD
Duke Cancer Institute
Durham, North Carolina

Treatment of Localized Colon Cancer
John M. Skibber, MD
The University of Texas MD Anderson Cancer Center
Houston, Texas

Adjuvant Treatment for Colorectal Cancer
Mary F. Mulcahy, MD
Robert H. Lurie Comprehensive Cancer Center of Northwestern University
Chicago, Illinois

Treatment of Metastatic Colorectal Cancer
Al B. Benson III, MD
Robert H. Lurie Comprehensive Cancer Center of Northwestern University
Chicago, Illinois

HEPATOCELLULAR CARCINOMA

Screening of High-Risk Patients and Surgical Options for Hepatocellular Carcinoma
Elin R. Sigurdson, MD, PhD
Fox Chase Cancer Center
Philadelphia, Pennsylvania

Selection of Systemic Therapy for Hepatocellular Carcinoma
Al B. Benson III, MD
Robert H. Lurie Comprehensive Cancer Center of Northwestern University
Chicago, Illinois

PANCREATIC CANCER

Treatment of Localized Pancreatic Cancer and Identification of High-Risk Patients
Sean J. Mulvihill, MD
Huntsman Cancer Institute at the University of Utah
Salt Lake City, Utah

Management of Metastatic Pancreatic Cancer
Margaret A. Tempero, MD
UCSF Helen Diller Family Comprehensive Cancer Center
San Francisco, California

GASTRIC/ESOPHAGEAL CANCER

Treatment of Localized Gastric/Esophageal Cancer: The Role of Neoadjuvant and Adjuvant Therapy
David H. Ilson, MD, PhD
Memorial Sloan-Kettering Cancer Center
New York, New York

Management of Metastatic Gastric/Esophageal Cancer
Jaffer A. Ajani, MD
The University of Texas MD Anderson Cancer Center
Houston, Texas

Program Overview



This educational program is designed to provide an in-depth analysis of the evidence and clinical decision-making that led to the development of the NCCN Guidelines™ for colon, rectal, hepatocellular, pancreatic, and gastric/esophageal cancers, collectively gastrointestinal cancers. Participants will learn how to implement the NCCN Guidelines recommendations into their practice and gain a clear understanding of the most up-to-date treatment recommendations for these cancers. As research continues in these areas and new information emerges, it is critical that clinicians are kept up-to-date and informed. This program will communicate the NCCN Guidelines in a direct and interactive way to community oncologists and other clinical professionals.

Educational Objectives



Following this activity, participants should be able to:

Treatment of Localized Rectal Cancer
  • Describe the current management strategies for locoregional rectal cancer
  • State the role of pre- and postoperative radiation in combination with chemotherapy in the management of rectal cancer


Treatment of Localized Colon Cancer
  • List the surgical options for a patient with localized colon cancer
  • Describe the role of lymphadenectomy in the surgical management of a patient with colon cancer


Adjuvant Treatment for Colorectal Cancer
  • Identify the risk factors that need to be considered to determine adjuvant therapy in patients with stage II colon cancer
  • Provide examples of current adjuvant chemotherapy options for patients with stage III colon cancer


Treatment of Metastatic Colorectal Cancer
  • List the factors that should be evaluated prior to selection of therapy for advanced colorectal cancer
  • Provide examples of chemotherapy regimens that are acceptable treatment options for patients with advanced colorectal cancer


Screening of High-Risk Patients and Surgical Options for Hepatocellular Carcinoma
  • Identify the characteristics of patients at high-risk for developing HCC and the appropriate tests used to screen these high-risk individuals for HCC


Selection of Systemic Therapy for Hepatocellular Carcinoma
  • Summarize the risk/benefits of various therapies for HCC and determine which treatments are appropriate for early vs. late stage disease


Treatment of Localized Pancreatic Cancer and Identification of High-Risk Patients
  • Identify risk factors and genetic syndromes that could lead to pancreatic cancer
  • Describe surgical management and criteria for resection for pancreatic cancer
  • Identify the role of adjuvant therapy and neoadjuvant therapy for patients with pancreatic cancer


Management of Metastatic Pancreatic Cancer
  • Explain general principles of chemotherapy for advanced pancreatic cancer
  • Provide the rationale for multidisciplinary management of symptoms for patients with pancreatic cancer
  • Describe palliative interventions that are unique to pancreatic cancer


Treatment of Localized Gastric/Esophageal Cancer: The Role of Neoadjuvant and Adjuvant Therapy
  • Discuss the role of combined modality treatments in the management of patients with localized esophageal and gastric cancers
  • Discuss the clinical evidence supporting the use of perioperative chemotherapy for gastroesophageal cancers


Management of Metastatic Gastric/Esophageal Cancer
  • Describe the treatment options and the role of capecitabine and oxaliplatin in the management of metastatic disease
  • Identify new targeted therapies and their mechanism of action and discuss the clinical evidence surrounding the use of targeted therapies in the management of advanced esophageal and gastric cancers


Intended Audience



This educational program is designed to meet the educational needs of oncologists, pathologists, nurses, pharmacists, and other health care professionals who manage patients with cancer.

Activity Instructions



Physicians and Pharmacists
This activity is composed of ten separate presentations. Continuing education credit will be awarded based on the number of presentations viewed and post-tests passed with a score of 80% or higher. Participants should review the learning objectives and faculty disclosure statement prior to viewing a presentation in its entirety. You must be connected to the Internet in order to review and complete the post-test and the evaluation form. A statement of credit will be electronically generated once you pass the post-test and complete the evaluation form. To receive credit, this activity must be completed no later than November 23, 2012. There is no fee for participating in this activity.

Nurses
This activity is composed of five individual presentations and three bundled presentations. Bundled presentations must be watched together to receive credit. Continuing education credit will be awarded based on the number of presentations viewed and post-tests passed with a score of 80% or higher. Participants should review the learning objectives and faculty disclosure statement prior to viewing a presentation in its entirety. You must be connected to the Internet in order to review and complete the post-test and the evaluation form. A statement of credit will be electronically generated once you pass the post-test and complete the evaluation form. To receive credit, this activity must be completed no later than November 23, 2012. There is no fee for participating in this activity.

Accreditation Information



Physicians

The National Comprehensive Cancer Network (NCCN) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education to physicians.

NCCN designates this enduring material for a maximum of 5.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Partial credit may be awarded as follows:

Treatment of Localized Rectal Cancer – 0.50 AMA PRA Category 1 Credit(s)™

Treatment of Localized Colon Cancer – 0.50 AMA PRA Category 1 Credit(s)™

Adjuvant Treatment for Colorectal Cancer – 0.50 AMA PRA Category 1 Credit(s)™

Treatment of Metastatic Colorectal Cancer – 0.50 AMA PRA Category 1 Credit(s)™

Screening of High-Risk Patients and Surgical Options for Hepatocellular Carcinoma – 0.50 AMA PRA Category 1 Credit(s)™

Selection of Systemic Therapy for Hepatocellular Carcinoma – 0.75 AMA PRA Category 1 Credit(s)™

Treatment of Localized Pancreatic Cancer and Identification of High-Risk Patients – 0.50 AMA PRA Category 1 Credit(s)™

Management of Metastatic Pancreatic Cancer – 0.50 AMA PRA Category 1 Credit(s)™

Treatment of Localized Gastric/Esophageal Cancer: The Role of Neoadjuvant and Adjuvant Therapy – 0.75 AMA PRA Category 1 Credit(s)™

Management of Metastatic Gastric/Esophageal Cancer – 0.25 AMA PRA Category 1 Credit(s)™

Release date: November 23, 2011
Expiration date: November 23, 2012

Nurses

The National Comprehensive Cancer Network is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

This activity is approved for 5.21 contact hours of continuing education for nurses.

Partial credit may be awarded as follows:

Bundle 1:
Treatment of Localized Colorectal Cancer – 0.92 contact hours
  • Treatment of Localized Rectal Cancer
  • Treatment of Localized Colon Cancer


Bundle 2:
Treatment of Advanced Colorectal Cancer – 1.01 contact hours
  • Adjuvant Treatment for Colorectal Cancer
  • Treatment of Metastatic Colorectal Cancer


Individual Presentations
Screening of High-Risk Patients and Surgical Options for Hepatocellular Carcinoma – 0.50 contact hours

Selection of Systemic Therapy for Hepatocellular Carcinoma – 0.64 contact hours

Treatment of Localized Pancreatic Cancer and Identification of High-Risk Patients – 0.61 contact hours

Management of Metastatic Pancreatic Cancer – 0.50 contact hours

Bundle 3:
Gastric/Esophageal Cancer – 1.03 contact hours
  • Treatment of Localized Gastric/Esophageal Cancer: The Role of Neoadjuvant and Adjuvant Therapy
  • Management of Metastatic Gastric/Esophageal Cancer


Approval as a provider refers to recognition of educational activities only and does not imply ANCC Commission on Accreditation approval or endorsement of any product.

Kristina M. Gregory, RN, MSN, OCN, is our nurse planner for this educational activity.

Release date: November 23, 2011
Expiration date: November 23, 2012

Pharmacists

Pharmacy Educational Objective
After completing this activity, the participant should be able to:
  • Provide accurate and appropriate counsel as part of the treatment team.


Accreditation Statement
National Comprehensive Cancer Network is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.


National Comprehensive Cancer Network designates this continuing education activity for a maximum of 5.25 contact hour(s) (0.525 CEUs) of continuing education credit in states that recognize ACPE accredited providers.

Type of Activity: Knowledge

Treatment of Localized Rectal Cancer – 0.50 contact hour(s) (0.05 CEUs)

Treatment of Localized Colon Cancer – 0.50 contact hour(s) (0.05 CEUs)

Adjuvant Treatment for Colorectal Cancer – 0.50 contact hour(s) (0.05 CEUs)

Treatment of Metastatic Colorectal Cancer – 0.50 contact hour(s) (0.05 CEUs)

Screening of High-Risk Patients and Surgical Options for Hepatocellular Carcinoma – 0.50 contact hour(s) (0.05 CEUs)

Selection of Systemic Therapy for Hepatocellular Carcinoma – 0.75 contact hour(s) (0.075 CEUs)

Treatment of Localized Pancreatic Cancer and Identification of High-Risk Patients – 0.50 contact hour(s) (0.05 CEUs)

Management of Metastatic Pancreatic Cancer – 0.50 contact hour(s) (0.05 CEUs)

Treatment of Localized Gastric/Esophageal Cancer: The Role of Neoadjuvant and Adjuvant Therapy – 0.75 contact hour(s) (0.075 CEUs)

Management of Metastatic Gastric/Esophageal Cancer – 0.25 contact hour(s) (0.025 CEUs)

Universal Activity Numbers:
Treatment of Localized Rectal Cancer – 0836-0000-11-030-H01-P

Treatment of Localized Colon Cancer – 0836-0000-11-031-H01-P

Adjuvant Treatment for Colorectal Cancer – 0836-0000-11-032-H01-P

Treatment of Metastatic Colorectal Cancer – 0836-0000-11-033-H01-P

Screening of High-Risk Patients and Surgical Options for Hepatocellular Carcinoma – 0836-0000-11-034-H01-P

Selection of Systemic Therapy for Hepatocellular Carcinoma – 0836-0000-11-035-H01-P

Treatment of Localized Pancreatic Cancer and Identification of High-Risk Patients – 0836-0000-11-036-H01-P

Management of Metastatic Pancreatic Cancer – 0836-0000-11-037-H01-P

Treatment of Localized Gastric/Esophageal Cancer: The Role of Neoadjuvant and Adjuvant Therapy – 0836-0000-11-038-H01-P

Management of Metastatic Gastric/Esophageal Cancer – 0836-0000-11-039-H01-P

Release date: November 23, 2011
Expiration date: November 23, 2012

Commercial Support



This activity is supported by an educational donation provided by Amgen.

Supported by educational grants from Bristol-Myers Squibb, Genentech BioOncology and OSI Oncology, Pfizer, and sanofi-aventis